|
1
|
Yu SY, Dong B, Fang ZF, Hu XQ, Tang L and
Zhou SH: Knockdown of lncRNA AK139328 alleviates myocardial
ischaemia/reperfusion injury in diabetic mice via modulating
miR-204-3p and inhibiting autophagy. J Cell Mol Med. 22:4886–4898.
2018. View Article : Google Scholar
|
|
2
|
Rowley WR and Bezold C: Creating public
awareness: State 2025 diabetes forecasts. Popul Health Manag.
15:194–200. 2012. View Article : Google Scholar
|
|
3
|
Rowley WR, Bezold C, Arikan Y, Byrne E and
Krohe S: Diabetes 2030: Insights from yesterday, today, and future
trends. Popul Health Manag. 20:6–12. 2017. View Article : Google Scholar
|
|
4
|
American Diabetes Association: Standards
of medical care in diabetes-2014. Diabetes Care. 37(Suppl 1):
S5–S13. 2014. View Article : Google Scholar
|
|
5
|
Ahlqvist E, van Zuydam NR, Groop LC and
McCarthy MI: The genetics of diabetic complications. Nat Rev
Nephrol. 11:277–287. 2015. View Article : Google Scholar
|
|
6
|
Navarro-González JF, Jarque A, Muros M,
Mora C and García J: Tumor necrosis factor-alpha as a therapeutic
target for diabetic nephropathy. Cytokine Growth Factor Rev.
20:165–173. 2009. View Article : Google Scholar
|
|
7
|
Alvarez ML and Distefano JK: The role of
non-coding RNAs in diabetic nephropathy: Potential applications as
biomarkers for disease development and progression. Diabetes Res
Clin Pract. 99:112013. View Article : Google Scholar
|
|
8
|
Del Ry S, Cabiati M, Raucci S, Simioniuc
A, Caselli C, Prescimone T and Giannessi D: Sequencing and cardiac
expression of Apelin in Sus Scrofa. Pharmacol Res. 60:314–319.
2009. View Article : Google Scholar
|
|
9
|
Fasshauer M and Blüher M: Adipokines in
health and disease. Trends Pharmacol Sci. 36:461–470. 2015.
View Article : Google Scholar
|
|
10
|
Lv D, Li H and Chen L: Apelin and APJ, a
novel critical factor and therapeutic target for atherosclerosis.
Acta Biochim Biophys Sin (Shanghai). 45:527–533. 2013. View Article : Google Scholar
|
|
11
|
Wysocka MB, Pietraszek-Gremplewicz K and
Nowak D: The role of apelin in cardiovascular diseases, obesity and
cancer. Front Physiol. 9:5572018. View Article : Google Scholar
|
|
12
|
Sentinelli F, Capoccia D, Bertoccini L,
Barchetta I, Incani M, Coccia F, Manconi E, Lenzi A, Cossu E,
Leonetti F, et al: Search for genetic variant in the apelin gene by
resequencing and association study in European subjects. Genet Test
Mol Biomarkers. 20:98–102. 2016. View Article : Google Scholar
|
|
13
|
Onalan E, Yakar B, Barım AO and Gursu MF:
Serum apelin and resistin levels in patients with impaired fasting
glucose, impaired glucose tolerance, type 2 diabetes, and metabolic
syndrome. Endokrynol Pol. 71:319–324. 2020.
|
|
14
|
Adki KM and Kulkarni YA: Potential
biomarkers in diabetic retinopathy. Curr Diabetes Rev. 16:971–983.
2020. View Article : Google Scholar
|
|
15
|
Wu R, Zhu Z and Zhou D: VEGF, apelin and
HO-1 in diabetic patients with retinopathy: A correlation analysis.
BMC Ophthalmol. 20:3262020. View Article : Google Scholar
|
|
16
|
Yasir M, Senthilkumar GP, Jayashree K,
Ramesh Babu K, Vadivelan M and Palanivel C: Association of serum
omentin-1, apelin and chemerin concentrations with the presence and
severity of diabetic retinopathy in type 2 diabetes mellitus
patients. Arch Physiol Biochem. Nov 5–2019.Epub ahead of print.
View Article : Google Scholar
|
|
17
|
Sabouri M, Norouzi J, Zarei Y, Sangani MH
and Hooshmand Moghadam B: Comparing high-intensity interval
training (HIIT) and continuous training on Apelin, APJ, NO, and
cardiotrophin-1 in cardiac tissue of diabetic rats. J Diabetes Res.
2020:14725142020. View Article : Google Scholar
|
|
18
|
Dawood AF, Sabry MM, Estaphan SA, Mohamed
EA, Younes SF, Rashed LA and Elzainy AW: Cross-talk between apelin
and vasopressin in response to different osmotic stimuli in type 2
diabetic rats. J Biol Regul Homeost Agents. 32:1117–1127. 2018.
|
|
19
|
National Research Council (US) Committee
for the Update of the Guide for the Care and use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press (US); Washington, DC: 2011
|
|
20
|
Chen Y, Lin L, Tao X, Song Y, Cui J and
Wan J: The role of podocyte damage in the etiology of
ischemia-reperfusion acute kidney injury and post-injury fibrosis.
BMC Nephrol. 20:1062019. View Article : Google Scholar
|
|
21
|
Xue M, Shi Y, Pang A, Men L, Hu Y, Zhou P,
Long G, Tian X, Wang R, Zhao Y, et al: Corin plays a protective
role via upregulating MAPK and downregulating eNOS in diabetic
nephropathy endothelial dysfunction. FASEB J. 34:95–106. 2020.
View Article : Google Scholar
|
|
22
|
Rossi L and Gesualdo L: Diabetic
nephropathy and cardiovascular risk. G Ital Nefrol. 34(Suppl 69):
S104–S118. 2017.In Italian.
|
|
23
|
Van Krieken R and Krepinsky JC: Caveolin-1
in the pathogenesis of diabetic nephropathy: Potential therapeutic
target? Curr Diab Rep. 17:192017. View Article : Google Scholar
|
|
24
|
Saran R, Robinson B, Abbott KC, Agodoa
LYC, Bhave N, Bragg-Gresham J, Balkrishnan R, Dietrich X, Eckard A,
Eggers PW, et al: US renal data system 2017 annual data report:
Epidemiology of kidney disease in the United States. Am J Kidney
Dis. 71(3 Suppl 1): A72018. View Article : Google Scholar
|
|
25
|
Khan NU, Lin J, Liu X, Li H, Lu W, Zhong
Z, Zhang H, Waqas M and Shen L: Insights into predicting diabetic
nephropathy using urinary biomarkers. Biochim Biophys Acta Proteins
Proteom. 1868:1404752020. View Article : Google Scholar
|
|
26
|
Castan-Laurell I, El Boustany R, Pereira
O, Potier L, Marre M, Fumeron F, Valet P, Gourdy P, Velho G and
Roussel R: Plasma Apelin and risk of type 2 diabetes in a cohort
from the community. Diabetes Care. 43:e15–e16. 2020. View Article : Google Scholar
|
|
27
|
Guo YY, Li T, Liu H, Tang L, Li YC, Hu HT,
Su YF, Lin Y, Wang YY, Li C, et al: Circulating levels of Elabela
and Apelin in the second and third trimesters of pregnancies with
gestational diabetes mellitus. Gynecol Endocrinol. 36:890–894.
2020. View Article : Google Scholar
|
|
28
|
Tanday N, Irwin N, Moffett RC, Flatt PR
and O'Harte FPM: Beneficial actions of a long-acting apelin
analogue in diabetes are related to positive effects on islet cell
turnover and transdifferentiation. Diabetes Obes Metab. 22. pp.
2468–2478. 2020, View Article : Google Scholar
|
|
29
|
Bae JH, Kwak SE, Lee JH, Yangjie Z and
Song W: Does exercise-induced apelin affect sarcopenia? A
systematic review and meta-analysis. Hormones (Athens). 18:383–393.
2019. View Article : Google Scholar
|
|
30
|
Sabry MM, Mahmoud MM, Shoukry HS, Rashed
L, Kamar SS and Ahmed MM: Interactive effects of apelin,
renin-angiotensin system and nitric oxide in treatment of
obesity-induced type 2 diabetes mellitus in male albino rats. Arch
Physiol Biochem. 125:244–254. 2019. View Article : Google Scholar
|
|
31
|
Ji B, Shang L, Wang C, Wan L, Cheng B and
Chen J: Roles for heterodimerization of APJ and B2R in promoting
cell proliferation via ERK1/2-eNOS signaling pathway. Cell Signal.
73:1096712020. View Article : Google Scholar
|
|
32
|
Nagib AM, El-Diasty A, El Husseny MA,
El-Gamal EM, Abbas MH, Refaie AF and Foudas MA: Apelin and
new-onset diabetes after transplant in living kidney allograft
recipients. Exp Clin Transplant. 13:319–323. 2015.
|
|
33
|
Huang Z, Luo X, Liu M and Chen L: Function
and regulation of apelin/APJ system in digestive physiology and
pathology. J Cell Physiol. 234:7796–7810. 2019. View Article : Google Scholar
|
|
34
|
Wakisaka M, Kamouchi M and Kitazono T:
Lessons from the trials for the desirable effects of sodium glucose
Co-transporter 2 inhibitors on diabetic cardiovascular events and
renal dysfunction. Int J Mol Sci. 20:56682019. View Article : Google Scholar
|
|
35
|
Li A, Peng R, Sun Y, Liu H, Peng H and
Zhang Z: LincRNA 1700020I14Rik alleviates cell proliferation and
fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α
signaling. Cell Death Dis. 9:4612018. View Article : Google Scholar
|
|
36
|
Zhou X, Ma L, Habibi J, Whaley-Connell A,
Hayden MR, Tilmon RD, Brown AN, Kim JA, Demarco VG and Sowers JR:
Nebivolol improves diastolic dysfunction and myocardial remodeling
through reductions in oxidative stress in the Zucker obese rat.
Hypertension. 55:880–888. 2010. View Article : Google Scholar
|
|
37
|
Wada J and Makino H: Innate immunity in
diabetes and diabetic nephropathy. Nat Rev Nephrol. 12:13–26. 2016.
View Article : Google Scholar
|
|
38
|
Niewczas MA, Pavkov ME, Skupien J, Smiles
A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ,
et al: A signature of circulating inflammatory proteins and
development of end-stage renal disease in diabetes. Nat Med.
25:805–813. 2019. View Article : Google Scholar
|
|
39
|
Mou Z, Feng Z, Xu Z, Zhuang F, Zheng X, Li
X, Qian J and Liang G: Schisandrin B alleviates diabetic
nephropathy through suppressing excessive inflammation and
oxidative stress. Biochem Biophys Res Commun. 508:243–249. 2019.
View Article : Google Scholar
|
|
40
|
Al Hroob AM, Abukhalil MH, Alghonmeen RD
and Mahmoud AM: Ginger alleviates hyperglycemia-induced oxidative
stress, inflammation and apoptosis and protects rats against
diabetic nephropathy. Biomed Pharmacother. 106:381–389. 2018.
View Article : Google Scholar
|
